Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized, Double-blind, Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of Iclepertin Once Daily Over 26 Week Treatment Period in Patients With Schizophrenia (CONNEX-3)

NCT04860830 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT04860830
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04860830 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized, Double-blind, Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of Iclepertin Once Daily Over 26 Week Treatment Period in Patients With Schizophrenia (CONNEX-3)
Lead sponsor
Boehringer Ingelheim
Phase
Phase 3
Overall status
Completed
Start date
August 9, 2021
Completion date
November 20, 2024
Enrollment
609 (actual)
Sites
110

Conditions

As the registry lists them; a condition with its own page is linked.

schizophrenia